Agilent Technologies (NYSE:A) Price Target Lowered to $130.00 at Citigroup

Agilent Technologies (NYSE:A – Get Rating) had its target price reduced by Citigroup from $150.00 to $130.00 in a report issued on Wednesday morning, The Fly reports. They currently have a neutral rating on the medical research company’s stock.

Other analysts have also issued reports about the stock. Barclays lowered their price target on shares of Agilent Technologies from $140.00 to $135.00 and set an equal weight rating on the stock in a research report on Wednesday. StockNews.com started coverage on shares of Agilent Technologies in a research report on Thursday, May 18th. They set a buy rating on the stock. Credit Suisse Group increased their price target on shares of Agilent Technologies from $165.00 to $170.00 and gave the stock an outperform rating in a research note on Wednesday, March 1st. Finally, Robert W. Baird raised their target price on shares of Agilent Technologies from $170.00 to $174.00 and gave the company an outperform rating in a research note on Wednesday, March 1st. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $151.35.

Agilent Technologies Stock Down 5.9 %

Shares of NYSE A opened at $120.99 on Wednesday. The firm has a market cap of $35.78 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 1.89 and a beta of 1.03. The company has a quick ratio of 1.53, a current ratio of 2.11 and a debt-to-equity ratio of 0.49. Agilent Technologies has a 52-week low of $112.52 and a 52-week high of $160.26. The business’s 50 day moving average is $133.87 and its two-hundred day moving average is $144.11.

Agilent Technologies (NYSE:A – Get Rating) last posted its quarterly earnings results on Tuesday, May 23rd. The medical research company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.26 by $0.01. The business had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.09% and a return on equity of 30.35%. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.13 earnings per share. Research analysts predict that Agilent Technologies will post 5.68 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Stockholders of record on Monday, July 3rd will be given a $0.225 dividend. The ex-dividend date is Friday, June 30th. This represents a $0.90 dividend on an annualized basis and a dividend yield of 0.74%. Agilent Technologies’s payout ratio is presently 20.32%.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the company. Delta Asset Management LLC TN acquired a new position in shares of Agilent Technologies in the fourth quarter valued at approximately $26,000. Money Concepts Capital Corp acquired a new stake in Agilent Technologies during the 4th quarter valued at approximately $26,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new stake in Agilent Technologies during the 4th quarter valued at approximately $27,000. Newbridge Financial Services Group Inc. increased its position in Agilent Technologies by 217.6% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 216 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 148 shares during the period. Finally, Ancora Advisors LLC acquired a new stake in Agilent Technologies during the 4th quarter valued at approximately $34,000.

About Agilent Technologies

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.